Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 10/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | PLEC | Q15149 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515676 | 0.80 | ALDH1A1 (0.45) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL514009 | 0.76 | HDAC1 (0.48) | KDM4EMAPTTP53THRBRAB9A | |
| SCHEMBL514330 | 0.76 | NPC1 (0.46) | KDM4EMAPTTP53RAB9ANPC1 | |
| SCHEMBL513443 | 0.76 | NPC1 (0.44) | KDM4EMAPTTP53RAB9ANPC1 | |
| SCHEMBL513766 | 0.75 | ALDH1A1 (0.40) | KDM4ETHRBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12689025 | 0.74 | KDM4E (0.48) | KDM4EMAPTTP53THRBRAB9A | |
| SCHEMBL9863815 | 0.73 | MAPT (0.37) | KDM4EMAPTTP53RAB9ANPC1 | |
| SCHEMBL512899 | 0.72 | KDM4E (0.48) | KDM4EMAPTTP53RAB9ANPC1 | |
| SCHEMBL15203949 | 0.70 | TSHR (0.38) | KDM4EMAPTRAB9ANPC1LMNA | |
| SCHEMBL4287937 | 0.69 | RAB9A (0.58) | KDM4EMAPTTP53THRBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | KDM4E 3490/4885MAPT 2573/4885TP53 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.